Acute graft-versus-host disease (aGVHD), the fatal side effects of bone marrow transplantation, was shown to be accompanied by elevation of serum levels of interleukin 18 (IL-18). In this study, the mechanism underlying the accumulation of IL-18 in aGVHD in mice was investigated. 
Introduction
Interleukin 18 (IL-18) is a cytokine with wide-ranging biologic functions that include activation not only of innate immunity, but also of acquired immunity, including both Th1 responses, particularly in collaboration with IL-12, and Th2 responses. [1] [2] [3] [4] [5] Furthermore, IL-18 is involved in the development of cytotoxic T lymphocytes and natural killer cells. [4] [5] [6] The regulatory mechanism of IL-18 secretion is distinct from that of usual secretory cytokines. 4, 5 IL-18 is stored as biologically inactive precursor (pro-IL-18) and is secreted after cleavage by appropriate cutting enzymes. 4, 5 Caspase-1 is a prerequisite for the secretion of IL-18 upon activation by certain stimuli, including lipopolysaccharide (LPS). [7] [8] [9] [10] Caspase-1-like is required for the secretion of IL-18 from Propionibacterium acnes-elicited Kupffer cells after stimulation with Fas ligand (FasL), although this study does not exclude the possible involvement of caspase-1. 11 Thus, the precise regulatory mechanism of IL-18 secretion is still uncertain. Recently, we and others have shown that the serum concentration of IL-18 is elevated in patients with acute graft-versus-host disease (aGVHD). 12, 13 In aGVHD, the Fas/FasL system plays an essential role in the development of fatal tissue injuries. 14, 15 Here, we investigated the mechanism underlying the accumulation of IL-18 in a mouse model of aGVHD and found that IL-18 is secreted in a FasL-initiated, caspase-1-dependent manner.
Study design
Mice C57BL/6 (B6) mice, B6XDBA/2 F1 (BDF1) mice, and BALB/c mice were purchased from SLC (Shizuoka, Japan). B6 gld/gld mice were purchased from CLEA Japan (Osaka, Japan). Caspase-1-deficient mice and wild-type (WT) littermates in a mixture of 129 and B6 background (B6/129) were used. 16 Caspase-1-deficient mice were back-crossed with BALB/c mice, and F8 mice were used. All of the mice used (females, 6-10 weeks old) were kept under specific pathogen-free conditions.
Reagents
L5178Y cells transfected with mouse FasL (mFasL) 11, 17 and neutralizing anti-mouse FasL monoclonal antibody (mAb; MFL-1, hamster IgG) 11, 17 were kindly provided by Dr N. Kayagaki (Juntendo University, Tokyo, Japan). 11 LPS derived from Escherichia coli 055:B5 was purchased from Difco (Detroit, MI). Culture medium generally used in this study was RPMI-1640 (Wako Pure Chemical, Osaka, Japan) supplemented with 10% fetal calf serum (JRH Bioscience, Lenexa, KS), 100 U/mL penicillin, 100 g/mL streptomycin, 50 M 2-mercaptoethanol, and 2 mM L-glutamine (Gibco BRL, Grand Island, NY).
Induction of aGVHD
aGVHD was induced by intravenous injection of 5 ϫ 10 7 viable, unfractionated donor spleen cells in lethally irradiated (9 Gy) recipients. Control mice received syngeneic (syn) spleen cells (5 ϫ 10 7 ).
Assay for IL-18
The concentration of IL-18 was determined by an enzyme-linked immunosorbent assay (ELISA) kit (MBL, Nagoya, Japan).
Preparation of Kupffer cells
Kupffer cells were isolated from variously treated mice as shown previously. 11 Kupffer cells (1 ϫ 10 6 /mL) were incubated with mFasL (1 ϫ 10 6 /mL) in the presence of 20 g/mL anti-mouse FasL or with 1 g/mL LPS for 24 hours.
Statistical analysis
The Student t test or the Fisher protected least significant difference test was performed. P Ͻ .05 was considered statistically significant.
Results and discussion

Elevated serum levels of IL-18 in aGVHD mice
As reported previously, levels of serum IL-18 are elevated in patients with aGVHD. 12, 13 This was also the case for mouse aGVHD. As shown in Figure 1A , IL-18 serum levels increased after transplantation of WT B6 spleen cells in 9 Gy-irradiated BDF1 mice (aGVHD-induced mice) and reached a plateau at day 10 (P Ͻ .0001 versus syngeneic controls). The serum levels of IL-18 correlated with the donor cell number infused, and the duration required for reaching their peaks became shortened (data not shown). Furthermore, there is a correlation between the concentration of serum IL-18 and the severity of pathologic changes in aGVHD target organs, such as spleen, liver, and intestines (H. I., unpublished data, August 2000). In contrast, IL-1␤, which is processed by the same enzymes that cleave pro-IL-18, 11, 18, 19 was not elevated in the serum of aGVHD-induced mice (data not shown). Therefore, high serum levels of IL-18 but not IL-1␤ seem to be an indicator of aGVHD not only in human patients, 12 but also in mouse experimental models.
Fas/FasL-mediated IL-18 secretion in aGVHD
As reported previously, Fas-expressing macrophages release biologically active IL-18 upon stimulation with FasL, depending on a non-caspase-1, caspace-dependent manner. 11 It has also been demonstrated that FasL-expressing cells were induced after induction of aGVHD. 14, 15 To investigate whether the Fas/FasL system is involved in the secretion of IL-18 in aGVHD, we transplanted splenocytes from gld/gld B6 mice, which lack functional FasL. As shown in Figure 1B , BDF1 mice having transplantation with gld/gld splenocytes did not show elevated serum levels of IL-18 compared with those engrafted with WT splenocytes (P Ͻ .01). No obvious increase in serum levels of IL-18 was observed by day 21 after transplantation with gld/gld splenocytes (data not shown). Furthermore, when 10-fold splenocytes from gld/gld B6 mice were transplanted into BDF1 mice, no significant elevation of serum IL-18 levels was observed by day 14 (data not shown). These results strongly suggest that IL-18 in aGVHD accumulates in a Fas/FasL-mediated fashion.
Next ) . Thus, the Fas/FasL system seems to play a role not only as an effector molecule involved in various tissue injuries including aGVHD, 14, 15, 20, 21 but also as a regulating factor prerequisite for the secretion of IL-18 in aGVHD.
Caspase-1-dependent IL-18 secretion after stimulation with FasL
Although, as we demonstrated previously, caspase-1-deficient Kupffer cells derived from P acnes-primed mice can secrete IL-18 after stimulation with FasL, 11 it is still possible that FasL stimulation might also activate caspase-1. Therefore, we investigated whether FasL-induced IL-18 accumulation in aGVHD is dependent on caspase-1. To test this possibility, we transplanted caspase-1-deficient or WT B6/129 spleen cells into caspase-1-deficient or WT BALB/c mice, respectively (Figure 2 ). Caspase-1-deficient hosts having transplantation with caspase-1-deficient cells showed only a slight elevation in serum levels of IL-18 ( Figure 2 , column D), whereas WT hosts having transplantation with WT cells contained high serum levels of IL-18 (column A), indicating caspase-1-dependent IL-18 release. Furthermore, IL-18 serum 
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were elevated in the WT hosts having transplantation with caspase-1-deficient donor cells (column B), whereas the inverse combination resulted in only a trace increase in the serum IL-18 concentration (column C). These data indicate that most of the elevated IL-18 in the circulation of aGVHD hosts is derived from hosts. Indeed, Kupffer cells from WT recipients engrafted with WT or caspase-1-deficient donor cells secreted IL-18 upon stimulation with mFasL, whereas those from caspase-1-deficient hosts secreted a trace amount of it, if any (data not shown). Moreover, only minor changes were observed in various target organs for aGVHD in caspase-1-deficient mice engrafted with WT or caspase-1-deficient allografts (H. I., unpublished data, December 2000). Therefore, IL-18 may be released from recipient cells in a FasL-mediated, caspase-1-dependent manner.
This is the first report that demonstrates FasL-mediated IL-18 accumulation in actually occurring diseases. As previously reported, pro-IL-18 is stored in Kupffer cells, 22 and IL-18 requires cleavage for its secretion by appropriate enzymes that are distinct depending on the sorts of stimuli. 7, 8, 11 The molecular basis of the processing of IL-18 is still unknown. A recent study demonstrated that upon stimulation with LPS, caspase-1 is activated via Toll-like receptor (TLR)-4, a signaling receptor for LPS, but independently of myeloid differentiation factor-88, an adaptor molecule for TLR-mediated signaling, leading to IL-18 secretion. 22 However, we do not yet know the signaling pathway after TLR-4 activation. This is also the case for FasL-induced IL-18 secretion. Our present study suggests that FasL-mediated IL-18 processing might consist of 2 pathways. One is a caspase-1-like-dependent pathway, and the other is the caspase-1-dependent pathway shown here. We do not know the mechanism for how FasL stimulation selectively activates caspase-1 in aGVHD-induced mice or how the same stimulation preferentially activates caspase-1-like in P acnes-primed mice. Perhaps, FasL-mediated activation of different caspases may be involved in the development of distinct pathophysiologic events, such as massive liver necrosis in P acnes/soluble FasL-treated mice 11 or severe bile duct destruction in aGVHD. 23 Caspase-1 might be a potential therapeutic target for manipulating aGVHD. We are now investigating the pathologic role of IL-18 in aGVHD. For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
